PMID- 27702625
OWN - NLM
STAT- MEDLINE
DCOM- 20181120
LR  - 20181120
IS  - 0925-4439 (Print)
IS  - 0925-4439 (Linking)
VI  - 1863
IP  - 8
DP  - 2017 Aug
TI  - Metformin, beyond an insulin sensitizer, targeting heart and pancreatic beta cells.
PG  - 1984-1990
LID - S0925-4439(16)30243-5 [pii]
LID - 10.1016/j.bbadis.2016.09.019 [doi]
AB  - Metformin, a biguanide derivate, is known as the first-line antidiabetic agent 
      for type 2 diabetes mellitus (T2DM) treatment. It reduces insulin resistance and 
      decreases blood glucose concentration by inhibiting gluconeogenesis and 
      suppressing hepatic glucose production with improved peripheral tissue insulin 
      sensitivity. As an insulin sensitizer, metformin takes pleiotropic actions and 
      exerts protective effects on multiple organs mainly in insulin-targeted tissues 
      such as liver, muscle, and adipose tissues. Recent studies discover that 
      metformin also plays essential roles in heart and pancreatic beta cells - two 
      important organs in metabolic regulation. Metformin not only protects T2DM 
      patients from cardiovascular diseases and heart failure, but also restores 
      insulin secretion activities and protects pancreatic beta cells from lipotoxicity or 
      glucotoxicity. Although accumulated evidence shed light on the metformin action, 
      the precise mechanism of metformin is still under investigation. Further 
      laboratory investigations and clinical trials are needed to pinpoint a map of 
      metformin action. Based on recent findings, this review characterizes the 
      beneficial role of metformin in cardiovascular diseases and pancreatic beta cells.
CI  - Copyright (c) 2016 Elsevier B.V. All rights reserved.
FAU - Yang, Xin
AU  - Yang X
AD  - Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan 410011, China; Metabolic Syndrome Research 
      Center, Key Laboratory of Diabetes Immunology, Ministry of Education, National 
      Clinical Research Center for Metabolic Diseases, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Xu, Zhipeng
AU  - Xu Z
AD  - Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan 410011, China; Metabolic Syndrome Research 
      Center, Key Laboratory of Diabetes Immunology, Ministry of Education, National 
      Clinical Research Center for Metabolic Diseases, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Zhang, Chunlan
AU  - Zhang C
AD  - Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan 410011, China; Metabolic Syndrome Research 
      Center, Key Laboratory of Diabetes Immunology, Ministry of Education, National 
      Clinical Research Center for Metabolic Diseases, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Cai, Zixin
AU  - Cai Z
AD  - Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan 410011, China; Metabolic Syndrome Research 
      Center, Key Laboratory of Diabetes Immunology, Ministry of Education, National 
      Clinical Research Center for Metabolic Diseases, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Zhang, Jingjing
AU  - Zhang J
AD  - Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan 410011, China; Metabolic Syndrome Research 
      Center, Key Laboratory of Diabetes Immunology, Ministry of Education, National 
      Clinical Research Center for Metabolic Diseases, Central South University, 
      Changsha, Hunan 410011, China. Electronic address: Doctorzhangjj@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20161001
PL  - Netherlands
TA  - Biochim Biophys Acta Mol Basis Dis
JT  - Biochimica et biophysica acta. Molecular basis of disease
JID - 101731730
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/metabolism/pathology/prevention & control
MH  - *Heart Failure/metabolism/pathology/prevention & control
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin-Secreting Cells/*metabolism/pathology
MH  - Metformin/*therapeutic use
MH  - Myocardium/*metabolism/pathology
OTO - NOTNLM
OT  - Heart failure
OT  - Insulin sensitizer
OT  - Metformin
OT  - Pancreatic beta Cells
EDAT- 2016/10/06 06:00
MHDA- 2018/11/21 06:00
CRDT- 2016/10/06 06:00
PHST- 2016/07/12 00:00 [received]
PHST- 2016/09/17 00:00 [revised]
PHST- 2016/09/27 00:00 [accepted]
PHST- 2016/10/06 06:00 [pubmed]
PHST- 2018/11/21 06:00 [medline]
PHST- 2016/10/06 06:00 [entrez]
AID - S0925-4439(16)30243-5 [pii]
AID - 10.1016/j.bbadis.2016.09.019 [doi]
PST - ppublish
SO  - Biochim Biophys Acta Mol Basis Dis. 2017 Aug;1863(8):1984-1990. doi: 
      10.1016/j.bbadis.2016.09.019. Epub 2016 Oct 1.